We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Upadacitinib
MedXY News
EnglishTag

Upadacitinib

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials
Allergy & ImmunologyJAK inhibitorsPhase 3 Clinical Trials

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials

By MedXY|Aug 17, 2026

Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights
Clinical Updatesreal‑world evidence
JAK inhibitors

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights

By MedXY|Aug 17, 2026

This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging cl

Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study
newspsoriatic arthritisUpadacitinib

Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study

By MedXY|Dec 4, 2025

In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with pri

Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis
Gastroenterologysafetyulcerative colitis

Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis

By MedXY|Oct 3, 2025

Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence
Clinical UpdatesGiant-cell arteritisJanus kinase inhibitors

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY|Oct 1, 2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unrespon

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities